PL3318267T3 - Środek leczniczy do leczenia zespołu huntera - Google Patents

Środek leczniczy do leczenia zespołu huntera

Info

Publication number
PL3318267T3
PL3318267T3 PL16818303T PL16818303T PL3318267T3 PL 3318267 T3 PL3318267 T3 PL 3318267T3 PL 16818303 T PL16818303 T PL 16818303T PL 16818303 T PL16818303 T PL 16818303T PL 3318267 T3 PL3318267 T3 PL 3318267T3
Authority
PL
Poland
Prior art keywords
therapeutic agent
hunter syndrome
syndrome therapeutic
hunter
agent
Prior art date
Application number
PL16818303T
Other languages
English (en)
Inventor
Jin-Kyung Lee
Han-Yeul BYUN
Myung-Eun Jung
Kyu-Hyun Lee
Original Assignee
Green Cross Corporation
Medigenebio Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corporation, Medigenebio Corporation filed Critical Green Cross Corporation
Priority claimed from PCT/KR2016/007203 external-priority patent/WO2017003270A1/ko
Publication of PL3318267T3 publication Critical patent/PL3318267T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16818303T 2015-07-02 2016-07-04 Środek leczniczy do leczenia zespołu huntera PL3318267T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562187867P 2015-07-02 2015-07-02
KR1020150187297A KR20170004814A (ko) 2015-07-02 2015-12-28 헌터증후군 치료제
PCT/KR2016/007203 WO2017003270A1 (ko) 2015-07-02 2016-07-04 헌터증후군 치료제 및 치료방법
EP16818303.6A EP3318267B1 (en) 2015-07-02 2016-07-04 Hunter syndrome therapeutic agent

Publications (1)

Publication Number Publication Date
PL3318267T3 true PL3318267T3 (pl) 2021-07-12

Family

ID=57833331

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16818303T PL3318267T3 (pl) 2015-07-02 2016-07-04 Środek leczniczy do leczenia zespołu huntera

Country Status (14)

Country Link
US (2) US10561713B2 (pl)
EP (1) EP3318267B1 (pl)
JP (2) JP6606199B2 (pl)
KR (3) KR20170004814A (pl)
CN (1) CN107921091A (pl)
CA (1) CA2990370C (pl)
CL (1) CL2018000002A1 (pl)
CO (1) CO2018000196A2 (pl)
EA (1) EA038110B1 (pl)
ES (1) ES2866957T3 (pl)
HK (1) HK1252663A1 (pl)
MX (1) MX379982B (pl)
PE (1) PE20190351A1 (pl)
PL (1) PL3318267T3 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094197C (en) 2015-07-02 2023-02-28 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ. ホフマン-ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
CN112074519B (zh) 2018-04-20 2024-08-02 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物
KR102671857B1 (ko) 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
AU2019357036B2 (en) * 2018-10-11 2024-11-14 Indivior Uk Limited Buprenorphine to treat respiratory depression
EP3826664A4 (en) * 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
AU2020454140A1 (en) 2020-06-16 2023-01-19 Novel Pharma Inc. Composition for treatment of glutaric aciduria and administration method therefor
KR20250080887A (ko) * 2022-12-29 2025-06-05 진동규 뮤코다당질 축적증에서의 안면 이형의 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011130A (es) 2009-04-22 2011-11-18 Alteogen Inc Proteina o peptido de fusion con vida media in vivo incrementada mantenido por liberacion in vivo sostenida, y metodo para incrementar la vida media in vivo usando el mismo.
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
UA115648C2 (uk) * 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Доставка терапевтичних агентів до цнс
PL2593131T3 (pl) * 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9682129B2 (en) 2011-12-23 2017-06-20 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
AU2013240306A1 (en) 2012-03-30 2014-10-09 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
JP2015013624A (ja) * 2013-07-08 2015-01-22 船井電機株式会社 手動推進器具

Also Published As

Publication number Publication date
JP6858231B2 (ja) 2021-04-14
US20180303914A1 (en) 2018-10-25
HK1252663A1 (zh) 2019-05-31
CL2018000002A1 (es) 2018-06-29
US20200093899A1 (en) 2020-03-26
US10561713B2 (en) 2020-02-18
PE20190351A1 (es) 2019-03-07
CA2990370C (en) 2022-05-17
BR112018000051A2 (pt) 2018-09-04
MX379982B (es) 2025-03-11
EP3318267A4 (en) 2019-02-27
JP6606199B2 (ja) 2019-11-13
KR20190141026A (ko) 2019-12-20
EA038110B1 (ru) 2021-07-07
KR20170004814A (ko) 2017-01-11
JP2020019775A (ja) 2020-02-06
CO2018000196A2 (es) 2018-03-28
JP2018519326A (ja) 2018-07-19
ES2866957T3 (es) 2021-10-20
MX2017016302A (es) 2018-03-23
CN107921091A (zh) 2018-04-17
KR102213055B1 (ko) 2021-02-08
EA201890182A1 (ru) 2018-06-29
EP3318267B1 (en) 2021-02-24
CA2990370A1 (en) 2017-01-05
KR20180015256A (ko) 2018-02-12
EP3318267A1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
IL250685A0 (en) Medicinal substance induces cytotoxicity
SG10201912416QA (en) Therapeutic agents
GB201515650D0 (en) Medicament delivery devices
GB201509893D0 (en) Therapeutic agents
GB201516442D0 (en) Combination therapy
PL3318267T3 (pl) Środek leczniczy do leczenia zespołu huntera
GB201517263D0 (en) Therapeutic agents
IL257976A (en) Combined treatment
ZA201804155B (en) Combination therapy
GB201509885D0 (en) Therapeutic agents
GB201502412D0 (en) Therapeutic use
SG10201912684TA (en) Therapeutic agent for fibrosis
GB201509888D0 (en) Therapeutic agents
IL250160A0 (en) medicinal substance
GB201513299D0 (en) Therapeutic agents
GB201516153D0 (en) Chewable medicament
GB201521767D0 (en) Therapeutic agents
GB201517264D0 (en) Therapeutic agents
GB201506786D0 (en) Therapeutic use
GB201911521D0 (en) Therapeutic agent
GB201516109D0 (en) Therapeutic agent
PT3290048T (pt) Agente indutor de imunidade
GB201702921D0 (en) Therapeutic agent
PT3326626T (pt) Agente para o tratamento de dermatomicose contendo citrato tripotássico
GB201504142D0 (en) Option administration